Frequently Asked Questions

Everything you need to know about LYRACELL.

These are the most frequently asked institutional questions about LYRACELL, the Moviglia Method and cell therapy in general. If your question is about a specific condition, you can find it on that treatment’s page.

1

Moviglia Method

The Moviglia Method is a cell therapy methodology that combines stem cells with immune system cells that have been previously selected and activated to direct the preparation toward the tissue being treated.

The base treatment is autologous: the stem cells come from the patient. Before they are applied, they are combined in the laboratory with immune system cells specific to the tissue being treated. This combination directs the stem cells to become the type of cell that tissue needs, and reproduces a repair mechanism that already exists naturally in the body. That is why the preparation is different for each tissue.

The base treatment is autologous: the mesenchymal stem cells come from the patient and are usually obtained from adipose tissue through a mini-liposuction. They can also be obtained from bone marrow or, if the patient had them stored at birth, from the umbilical cord or placenta. The immune system cells are obtained from a blood sample from the patient. In certain cases, depending on the medical indication, immune system cells from a selected donor may be used.

No. The Moviglia Method does not modify the patient’s genome.

No. The indication depends on an individual medical evaluation and the characteristics of the diagnosis.

The number of applications is defined at the start according to the tissue to be treated, which makes it possible to establish a treatment plan with specific goals. At the end of that plan, the corresponding assessments are carried out and, if needed, further interventions are defined. Since the stem cells come from the patient, the treatment can be repeated when the medical team indicates it.

2

LYRACELL Lab

LYRACELL Lab is LYRACELL’s in-house laboratory, dedicated to processing and preparing the cells used in each treatment according to the protocols of the Moviglia Method.

The cells are identified, separated, processed and quantified according to the tissue defined in the treatment proposal. Quality controls are also carried out before they are released.

They are classifications related to air quality and particle control in environments where processes requiring controlled conditions are carried out. LYRACELL Lab works with ISO 5 air quality in production and ISO 7 in pre-production.

LYRACELL Lab can process stem cells from different tissues and immune system cells. Their origin and preparation are defined according to the corresponding protocol and each patient’s medical indication.

No. LYRACELL Lab does not modify the genome of the cells.

No. Each application requires prior preparation. The laboratory begins working several days in advance and coordinates the timing of cell activation and preparation with the scheduled treatment date.

Yes. The protocol includes serological tests of the patient before and after treatment.

Yes. Certain cell populations can be cryopreserved to keep them available for the following stages of the protocol, according to the corresponding indication.

3

Research and Publications

The main lines of research are:

  • Cell selection and expansion.
  • Biological mechanisms involved in cell differentiation, such as the interaction between different cell populations and with biological matrices.
  • Clinical application of regenerative medicine strategies in different conditions.
  • Evaluation and follow-up of regenerative medicine interventions.

LYRACELL carries out this work in partnership with ACIDTA, integrating research and clinical practice.

Its development brings together more than 20 years of scientific work and publications in international scientific journals such as Science Advances and Journal of Neurorestoratology.

No. A publication provides evidence about a specific population, protocol or condition. Whether the treatment may be indicated must be defined through an individual medical evaluation.

On the Research and Publications page, with direct access to the DOI or original source of each paper.

4

Our Team

Dr. Teresita Moviglia, clinical immunologist and president of ACIDTA, together with the LYRACELL medical team.

A team of ten professionals that includes orthopedics, general surgery, diagnostic imaging, interventional medicine, clinical neurophysiology and aesthetic medicine, depending on each patient’s diagnosis. You can meet each professional on Medical and Scientific Team.

Through an initial remote evaluation, coordinated before planning the trip to Buenos Aires.

5

International Patients

Yes. The evaluation begins remotely, with no need to travel (more details on International Patients):

  1. Sending your medical information. You share your medical history and any studies you already have with our team (for example, lab tests, X-rays, MRIs or ultrasounds).
  2. Virtual interview. We schedule a video call with a physician from our team, who reviews your case and answers your questions.
  3. Treatment proposal. If cell therapy may be indicated, we send you a personalized proposal.
  4. Travel to Buenos Aires. If you accept the proposal, we coordinate your trip. When you arrive, the team completes the clinical evaluation and confirms the plan before starting.

No. Concierge is an optional service contracted separately. Its scope is adapted to each patient’s needs and may include coordinating transfers, bilingual assistance in Spanish and English, and suggestions for free time, always subject to the medical schedule.

You do not have to travel with a companion. If you travel alone and a procedure requires someone to accompany you, we can arrange for a nurse to assist you for as long as necessary. In addition, our team supports you at every stage and you have phone assistance throughout the treatment.

Medical care and coordination are provided in Spanish and English.

The treatment proposal indicates how many days you need to stay in Buenos Aires. Depending on the case, the stay can range from three days to a few weeks. We always aim to keep it as short as possible, while respecting the time each stage of treatment requires.

Our team carries out remote check-ups through virtual consultations and, when necessary, coordinates follow-up with your treating physician and other professionals in your country, always with your authorization. Depending on your case, control studies may also be ordered to assess your progress.

6

Medical Partners

No. First, the LYRACELL medical team evaluates the case. Only if the patient is a candidate for cell therapy do we send you a treatment proposal with its rationale, goals and limitations. A joint interview is then held between you, your patient and a physician from our team, and the decision to proceed is the patient’s.

No. You remain your patient’s treating physician. Our team complements your approach with its experience in cell therapy and regenerative medicine. With the patient’s authorization, we stay in touch with you to support the continuity of their care.

The diagnosis, a summary of the medical history (relevant background and progress) and the available studies, always with the patient’s authorization. If necessary, our team may request additional studies.

Yes, always with the patient’s authorization. We agree with you on the method and frequency of communication according to the needs of each case. Follow-up is carried out jointly with you.

Yes. You can talk with the LYRACELL medical team before making a formal referral to guide the next steps. Learn about the process on Medical Partners.

Your next step

Didn’t find your answer?

Request a medical evaluation and get your questions answered directly by the team.